Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Metro G, Baglivo S, Bellezza G, Mandarano M, Gili A, Marchetti G, Toraldo M, Molica C, Reda MS, Tofanetti FR, Siggillino A, Prosperi E, Giglietti A, Di Girolamo B, Garaffa M, Marasciulo F, Minotti V, Gunnellini M, Guida A, Sassi M, Sidoni A, Roila F, Ludovini V. Metro G, et al. Among authors: gili a. Genes (Basel). 2021 Apr 30;12(5):679. doi: 10.3390/genes12050679. Genes (Basel). 2021. PMID: 33946594 Free PMC article.
Targeting EGFR and ALK in NSCLC: current evidence and future perspective.
Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Bennati C, et al. Among authors: gili a. Lung Cancer Manag. 2016 Jun;5(2):79-90. doi: 10.2217/lmt-2016-0005. Epub 2016 Jun 23. Lung Cancer Manag. 2016. PMID: 30643552 Free PMC article. Review.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. Metro G, et al. Among authors: gili a. J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23. J Thorac Dis. 2019. PMID: 32030213 Free PMC article.
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Mandarano M, Bellezza G, Belladonna ML, Vannucci J, Gili A, Ferri I, Lupi C, Ludovini V, Falabella G, Metro G, Mondanelli G, Chiari R, Cagini L, Stracci F, Roila F, Puma F, Volpi C, Sidoni A. Mandarano M, et al. Among authors: gili a. Front Immunol. 2020 May 27;11:839. doi: 10.3389/fimmu.2020.00839. eCollection 2020. Front Immunol. 2020. PMID: 32536910 Free PMC article.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Friedlaender A, et al. Among authors: gili a. Acta Oncol. 2020 Sep;59(9):1058-1063. doi: 10.1080/0284186X.2020.1781249. Epub 2020 Jun 17. Acta Oncol. 2020. PMID: 32762415
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. Metro G, et al. Among authors: gili a. J Immunother. 2020 Nov/Dec;43(9):299-306. doi: 10.1097/CJI.0000000000000340. J Immunother. 2020. PMID: 32991393
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
Metro G, Gili A, Signorelli D, De Toma A, Garaffa M, Galetta D, Economopoulou P, Friedlaender A, Jimenez B, Collazo-Lorduy A, Addeo A, Chiarini P, Costa C, Mountzios G, Roila F. Metro G, et al. Among authors: gili a. Clin Transl Oncol. 2021 Sep;23(9):1818-1826. doi: 10.1007/s12094-021-02588-8. Epub 2021 Mar 16. Clin Transl Oncol. 2021. PMID: 33728869
Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
Baglivo S, Bianconi F, Metro G, Gili A, Tofanetti FR, Bellezza G, Ricciuti B, Mandarano M, Teti V, Siggillino A, Reda MS, Chiari R, Pistola L, Sidoni A, Minotti V, Roila F, Ludovini V. Baglivo S, et al. Among authors: gili a. Genes (Basel). 2021 Jun 29;12(7):992. doi: 10.3390/genes12070992. Genes (Basel). 2021. PMID: 34209514 Free PMC article.
A New Medium (HistoCold) for Surgical Specimens Preserving to Improve the Preanalytic Issues in Histopathological Samples Handling: Morphologic and Antigenic Analysis.
Mandarano M, Pelliccia C, Tomasello L, Caselli E, Floridi C, Loreti E, Barberini F, Rulli A, Gili A, Potenza R, Puma F, Rosati E, Donini A, Petrina A, Baccari P, Del Sordo R, Colella R, Bellezza G, Sidoni A. Mandarano M, et al. Among authors: gili a. Biopreserv Biobank. 2023 Dec;21(6):610-623. doi: 10.1089/bio.2022.0128. Epub 2023 May 16. Biopreserv Biobank. 2023. PMID: 37192479
87 results